Search

Author/Creator Morand, Eric F

21. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Issue 10381 (25th March 2023)

Authors:
Petri, Michelle; Bruce, Ian N; Dörner, Thomas; Tanaka, Yoshiya; Morand, Eric F; Kalunian, Kenneth C; Cardiel, Mario H; Silk, Maria E; Dickson, Christina L; Meszaros, Gabriella; Zhang, Lu; Jia, Bochao; Zhao, Youna; McVeigh, Conor J; Mosca, Marta
Journal:
Lancet
Issue:
Volume 401:Issue 10381(2023)
Page Start:
1011
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

25. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. (March 2022)

Authors:
Strand, Vibeke; O'Quinn, Sean; Furie, Richard A; Morand, Eric F; Kalunian, Kenneth C; Schwetje, Erik G; Abreu, Gabriel; Tummala, Raj
Journal:
Lancet
Issue:
Volume 4:Number 3(2022)
Page Start:
e198
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

29. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Issue 7 (17th May 2022)

Authors:
Bruce, Ian N; Furie, Richard A; Morand, Eric F; Manzi, Susan; Tanaka, Yoshiya; Kalunian, Kenneth C.; Merrill, Joan T; Puzio, Patricia; Maho, Emmanuelle; Kleoudis, Christi; Albulescu, Marius; Hultquist, Micki; Tummala, Raj
Journal:
Annals of the rheumatic diseases
Issue:
Volume 81:Issue 7(2022)
Page Start:
962
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗